RECODE · 연구동향생성일 2026-10-31

연구동향

기준 논문: Clinical Data Interchange Standards in Clinical Trials on Alzheimer's Disease

Psychiatry Investig 19(10):814-823 · 2022 · PMID 36327961

검색 방법

이 논문의 제목과 주제어를 바탕으로 이 논문이 속한 연구 분야를 묻는 질문을 만들어 ReviewFast에 넣어 2026-10-31에 검색했습니다. ReviewFast가 PubMed를 검색하고, AI 모델(Jev)이 제목과 초록을 읽어 질문과의 관련도를 매긴 뒤 주제별로 묶었습니다.

1,613편 검색→1,574편 판독→170편 선별 (관련도 0.5 이상)

질문과 PubMed 검색식 보기질문: Data standards in Alzheimer disease trials Data standards in Alzheimer disease trials

출판 연도

1996: 1편119961997: 2편220002001: 3편32004: 1편120052006: 3편32008: 4편42009: 2편22010: 6편620102011: 8편82012: 6편62013: 8편82014: 5편52015: 16편1620152016: 3편32017: 6편62018: 5편52019: 11편112020: 3편320202021: 10편102022: 6편62023: 5편52024: 18편182025: 24편242026: 14편142026

선별된 170편의 출판 연도. 검색일(2026-10-31) 기준이며, 그 이후 논문은 들어 있지 않습니다.

주제별 논문

주제 이름은 ReviewFast가 초록의 단어로 자동으로 붙인 것입니다. 왼쪽 숫자는 관련도(0–1)입니다. RECODE 는 우리 연구팀 논문입니다.

01drug · development49편

  1. 0.90

    Development of a unified clinical trial database for Alzheimer's disease

    Neville J, Kopko S, Broadbent S et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  2. 0.88

    Implementing the National Alzheimer's Coordinating Center Uniform Data Set (v3) within the Diabetes Prevention Program Outcomes Study

    Doherty LK, Dechiario I, Sherif H et al. · Neuroepidemiology · 2026

  3. 0.86

    Accelerating drug development for Alzheimer's disease through the use of data standards

    Neville J, Kopko S, Romero K et al. · Alzheimer's & dementia (New York, N. Y.) · 2017

  4. 0.86

    Alzheimer's clinical research data via R packages: The alzverse

    Donohue MC, Hussen K, Langford O et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  5. 0.85

    Estimating Socio-Economic Status for Alzheimer's Disease Trials

    Rentz DM, Grill JD, Molina-Henry DP et al. · The journal of prevention of Alzheimer's disease · 2024

  6. 0.84

    MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols

    Wilcock D, Jicha G, Blacker D et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021

  7. 0.82

    Artificial intelligence-enabled safety monitoring in Alzheimer's disease clinical trials

    Jimenez-Maggiora GA, Donohue MC, Rafii MS et al. · The journal of prevention of Alzheimer's disease · 2025

  8. 0.81

    The Data Gap in the EHR for Clinical Research Eligibility Screening

    Butler A, Wei W, Yuan C et al. · AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2018

  9. 0.81

    Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment

    Lyketsos CG, Roberts SB, Swift EK et al. · The journal of prevention of Alzheimer's disease · 2022

  10. 0.76

    Using historical data to facilitate clinical prevention trials in Alzheimer disease? An analysis of longitudinal MCI (mild cognitive impairment) data sets

    Berres M, Monsch AU, Spiegel R · Alzheimer's research & therapy · 2021

  11. 0.73

    Worldwide Alzheimer's disease neuroimaging initiative

    Carrillo MC, Bain LJ, Frisoni GB et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2012

  12. 0.72

    Generating real-world evidence in Alzheimer's disease: Considerations for establishing a core dataset

    Galvin JE, Cummings JL, Benea ML et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

  13. 0.71

    The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update

    Hendrix JA, Finger B, Weiner MW et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  14. 0.71

    Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

    Weiner MW, Veitch DP, Aisen PS et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  15. 0.71

    Impact of non-binding FDA guidances on primary endpoint selection in Alzheimer's disease trials

    Yu JC, Hlavka JP, Joe E et al. · Alzheimer's & dementia (New York, N. Y.) · 2022

  16. 0.70

    Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network

    Kornhuber J, Schmidtke K, Frolich L et al. · Dementia and geriatric cognitive disorders · 2009

  17. 0.68

    Dementia patient and caregiver relevant outcomes currently being reported by adult day service centers in the United States

    Sadarangani T, Anderson K, Westmore MR et al. · Alzheimer's & dementia (New York, N. Y.) · 2022

  18. 0.67

    Improving data sharing in research with context-free encoded missing data

    Hoevenaar-Blom MP, Guillemont J, Ngandu T et al. · PloS one · 2017

  19. 0.66

    The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

    Weber CJ, Carrillo MC, Jagust W et al. · Alzheimer's & dementia (New York, N. Y.) · 2021

  20. 0.66

    MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols

    Lu H, Kashani AH, Arfanakis K et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021

  21. 0.66

    Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project

    Gallacher J, de Reydet de Vulpillieres F, Amzal B et al. · Journal of Alzheimer's disease : JAD · 2019

  22. 0.65

    Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines

    Antuono P, Doody R, Gilman S et al. · Alzheimer disease and associated disorders · 1997

  23. 0.64

    Study design considerations: conducting global clinical trials in early Alzheimer's disease

    Schindler RJ · The journal of nutrition, health & aging · 2010

  24. 0.63

    Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease

    Jack CRJ, Barkhof F, Bernstein MA et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2011

  25. 0.63

    Overcoming challenges to data quality in the ASPREE clinical trial

    Lockery JE, Collyer TA, Reid CM et al. · Trials · 2019

  26. 0.63

    Recommendations on Imaging in the Context of Alzheimer's Disease-Modifying Therapies from the CCNA Imaging Workgroup

    Duchesne S, Collins DL, Barlow L et al. · The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2024

  27. 0.62

    Imago Mundi, Imago AD, Imago ADNI

    Villemagne VL, Kim SY, Rowe CC et al. · Alzheimer's research & therapy · 2014

  28. 0.62

    Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets

    Evans S, McRae-McKee K, Hadjichrysanthou C et al. · Alzheimer's & dementia (New York, N. Y.) · 2019

  29. 0.62

    Evaluating linked ICD-10 Medicare claims data as a method of dementia case ascertainment in research settings

    Bhattacharyya J, Barnes LL, Chen Y et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  30. 0.61

    Task force on Alzheimer's disease trial methodology: recruitment and retention, data management and analysis. The use of imaging in recruitment: maintenance and methodological issues in Alzheimer's trials

    Suhy J · The journal of nutrition, health & aging · 2012

  31. 0.61

    Clinical trials for neuropsychiatric syndromes in major and mild neurocognitive disorders: A CONSORT-based approach

    Cummings JL, Zhong K, Ballard C et al. · International psychogeriatrics · 2025

  32. 0.61

    Contributions of the ADNI Biostatistics Core

    Beckett LA, Saito N, Donohue MC et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

  33. 0.61

    Standardizing "Rapid": Applying the Clinical Dementia Rating to Define Rapidly Progressive Dementia

    Satyadev N, Piura YD, Tipton PW et al. · Neurology · 2026

  34. 0.60

    Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease

    Lansdall CJ, Teng E, Chague J et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

  35. 0.60

    Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network

    Cummings J, Aisen P, Barton R et al. · The journal of prevention of Alzheimer's disease · 2016

  36. 0.60

    Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans

    Aisen PS, Petersen RC, Donohue M et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  37. 0.59

    Endpoints for trials in Alzheimer's disease: a European task force consensus

    Vellas B, Andrieu S, Sampaio C et al. · The Lancet. Neurology · 2008

  38. 0.58

    Influence of Different Diagnostic Criteria on Alzheimer Disease Clinical Research

    Bieger A, Brum WS, Borelli WV et al. · Neurology · 2024

  39. 0.57

    Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force

    Kaye J, Aisen P, Amariglio R et al. · The journal of prevention of Alzheimer's disease · 2021

  40. 0.56

    Closed-form confidence intervals for saved time using summary statistics in Alzheimer's disease studies

    Shan G, Zhang Y, Wang G et al. · Statistical methods in medical research · 2025

  41. 0.55

    Alzheimer's disease drug development: old problems require new priorities

    Becker RE, Greig NH · CNS & neurological disorders drug targets · 2008

  42. 0.55

    Perspectives from Alzheimer's Disease Research Centers site directors on the early steps and the lasting impact

    Growdon JH, Morris JC, Petersen RC et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  43. 0.55

    Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America

    Kikuchi M, Adachi N, Matsumaru N et al. · Pharmaceutical medicine · 2019

  44. 0.55

    Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey

    Rockwood K, Black SE, Robillard A et al. · International journal of geriatric psychiatry · 2004

  45. 0.52

    Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs

    Callahan CM, Tu W, Stump TE et al. · Alzheimer disease and associated disorders · 2015

  46. 0.51

    PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative

    Shaw LM · Neuro-Signals · 2008

  47. 0.51

    Racial and Ethnic Reporting and Representation in Phase III Alzheimer's Disease Clinical Trials in the US

    Lin Z, Sun R, Ross JS et al. · medRxiv : the preprint server for health sciences · 2025

  48. 0.50

    Development of a core outcome set for clinical trials of interventions to improve sleep in people with cognitive impairment-the Sleep in Cognitive Impairment Core Outcome Set (SCICOS)

    Crowley P, Henry AL, Flanagan E et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  49. 0.50

    Power calculations for clinical trials in Alzheimer's disease

    Ard MC, Edland SD · Journal of Alzheimer's disease : JAD · 2011

02pet · emission tomography45편

  1. 0.85

    Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach

    Royse SK, Minhas DS, Lopresti BJ et al. · Alzheimer's research & therapy · 2021

  2. 0.84

    Establishment of Dementia Platform Korea and the Trial Ready Registry to advance Alzheimer's disease research in Korea RECODE

    Kim HJ, Kim KW, Seo SW et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  3. 0.82

    Longitudinal head-to-head comparison of (11)C-PiB and (18)F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-beta monoclonal antibodies in dominantly inherited Alzheimer's disease

    Chen CD, McCullough A, Gordon B et al. · European journal of nuclear medicine and molecular imaging · 2023

  4. 0.82

    Phantom criteria for qualification of brain FDG and amyloid PET across different cameras

    Ikari Y, Akamatsu G, Nishio T et al. · EJNMMI physics · 2016

  5. 0.81

    Positron emission tomography harmonization in the Alzheimer's Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification

    Landau SM, Harrison TM, Baker SL et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  6. 0.80

    The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods

    Jack CRJ, Bernstein MA, Fox NC et al. · Journal of magnetic resonance imaging : JMRI · 2008

  7. 0.79

    The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

    Jagust WJ, Landau SM, Koeppe RA et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  8. 0.78

    Overview of ADNI MRI

    Jack CRJ, Arani A, Borowski BJ et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

  9. 0.78

    The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core

    Jagust WJ, Bandy D, Chen K et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2010

  10. 0.76

    Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers

    Landau SM, Thomas BA, Thurfjell L et al. · European journal of nuclear medicine and molecular imaging · 2014

  11. 0.76

    Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation

    Johns E, Vossler HA, Young CB et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

  12. 0.75

    A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research

    Iaccarino L, Burnham SC, Tunali I et al. · NeuroImage. Clinical · 2025

  13. 0.74

    Evaluation of ComBat Harmonization for Reducing Across-Tracer Differences in Regional Amyloid PET Analyses

    Yang B, Earnest T, Kumar S et al. · Human brain mapping · 2024

  14. 0.74

    The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data

    Schmidt ME, Chiao P, Klein G et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  15. 0.74

    Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease

    Herholz K · Biomarkers in medicine · 2012

  16. 0.73

    Quantitative analysis of PiB-PET with FreeSurfer ROIs

    Su Y, D'Angelo GM, Vlassenko AG et al. · PloS one · 2013

  17. 0.72

    AI-enhanced Centiloid quantification of amyloid PET images

    Bourgeat P, Fripp J, Lebrat L et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  18. 0.72

    Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy

    Zhang J, Soleimani-Meigooni DN, Koeppe R et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025

  19. 0.72

    Revisiting Centiloids using AI

    Bourgeat P, Fripp J, Lebrat L et al. · Research square · 2025

  20. 0.70

    Decomposition-based harmonization for quantitative PET imaging across scanners and radiotracers

    Zhao S, Huang Q, Nie B et al. · Medical physics · 2026

  21. 0.68

    Comparison of (18)F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL((R)) approaches: Validation against histopathology

    Dore V, Bullich S, Rowe CC et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019

  22. 0.68

    Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials

    Tryputsen V, DiBernardo A, Samtani M et al. · Journal of Alzheimer's disease : JAD · 2015

  23. 0.68

    Evaluation of (18)F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer's disease

    Sur C, Adamczuk K, Scott D et al. · Molecular imaging and biology · 2022

  24. 0.67

    rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data

    Iaccarino L, La Joie R, Koeppe R et al. · NeuroImage · 2022

  25. 0.65

    Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis

    Blazhenets G, Soleimani-Meigooni DN, Chiotis K et al. · JAMA · 2026

  26. 0.65

    Automated PET tracer classification in multi-site, multi-cohort studies using deep learning

    Gebre RK, Reid RI, Senjem ML et al. · EJNMMI research · 2026

  27. 0.65

    Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads

    Thurfjell L, Lilja J, Lundqvist R et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014

  28. 0.64

    A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease

    Ruppert E, Vermeiren MR, Scop Medeiros M et al. · JAMA neurology · 2026

  29. 0.64

    Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio

    Cselenyi Z, Farde L · Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2015

  30. 0.63

    Towards multicenter beta-amyloid PET imaging in mouse models: A triple scanner head-to-head comparison

    Gnorich J, Koehler M, Wind-Mark K et al. · NeuroImage · 2024

  31. 0.63

    Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template

    Lilja J, Leuzy A, Chiotis K et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019

  32. 0.63

    Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study

    Osadebey ME, Pedersen M, Arnold DL et al. · BMC medical imaging · 2018

  33. 0.62

    Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification

    Presotto L, Iaccarino L, Sala A et al. · NeuroImage. Clinical · 2018

  34. 0.61

    Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab

    Chiao P, Bedell BJ, Avants B et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019

  35. 0.61

    petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI

    Coupe P, Mansencal B, Morandat F et al. · Alzheimer's research & therapy · 2025

  36. 0.59

    A Semiautomated Method for Quantification of F 18 Florbetapir PET Images

    Joshi AD, Pontecorvo MJ, Lu M et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015

  37. 0.58

    Head-to-head comparison of tau PET tracers [(18)F]PI-2620 and [(18)F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort

    Tonietto M, Sotolongo-Grau O, Roe-Vellve N et al. · Alzheimer's research & therapy · 2024

  38. 0.58

    Resting-state functional magnetic resonance imaging in a randomized clinical trial for Alzheimer's disease

    Clayton D, Coimbra A, Faraji F et al. · Neuroimage. Reports · 2021

  39. 0.55

    Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [(18)F] flutemetamol amyloid PET study

    Hanseeuw BJ, Malotaux V, Dricot L et al. · European journal of nuclear medicine and molecular imaging · 2021

  40. 0.54

    A novel method for harmonization of PET image spatial resolution without phantoms

    Carbonell F, Zijdenbos AP, Hempel E et al. · EJNMMI physics · 2025

  41. 0.54

    Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

    Fleisher AS, Joshi AD, Sundell KL et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017

  42. 0.53

    Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease

    Wang G, Li Y, Xiong C et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

  43. 0.52

    Development and Validation of a (18)F-Flortaucipir PET Visual Stratification Method

    Tunali I, Wang J, Arora AK et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025

  44. 0.51

    Operationalizing postmortem pathology-MRI association studies in Alzheimer's disease and related disorders with MRI-guided histology sampling

    Athalye C, Bahena A, Khandelwal P et al. · Acta neuropathologica communications · 2025

  45. 0.51

    Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images

    Carbonell F, Zijdenbos AP, Charil A et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015

03test · scores40편

  1. 0.85

    Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS)

    Weintraub S, Besser L, Dodge HH et al. · Alzheimer disease and associated disorders · 2018

  2. 0.80

    Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease

    Gauthier S, Lopez OL, Waldemar G et al. · International psychogeriatrics · 2010

  3. 0.79

    The Alzheimer's disease activities of daily living international scale (ADL-IS)

    Reisberg B, Finkel S, Overall J et al. · International psychogeriatrics · 2001

  4. 0.77

    Psychometric comparison of standard and computerized administration of the Alzheimer's Disease Assessment Scale: Cognitive Subscale (ADASCog)

    O'Halloran JP, Kemp AS, Salmon DP et al. · Current Alzheimer research · 2011

  5. 0.76

    Bridging the gap: A conversion framework for CDR-SB and MoCA scores in Alzheimer's disease and related dementia

    Haji B, Zhang Q, Tahami Monfared AA · The journal of prevention of Alzheimer's disease · 2025

  6. 0.76

    Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease

    Wesnes K, Edgar C, Andreasen N et al. · Acta neurologica Scandinavica · 2010

  7. 0.73

    Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials

    Coley N, Andrieu S, Jaros M et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2011

  8. 0.73

    Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience

    Morris JC, Ernesto C, Schafer K et al. · Neurology · 1997

  9. 0.68

    Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE(R) AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales

    Hendrix S, Ellison N, Stanworth S et al. · The journal of prevention of Alzheimer's disease · 2015

  10. 0.68

    The Utility of Episodic Memory Cut-Off Scores for Inclusion in Clinical Trials for Early Symptomatic Alzheimer Disease

    Randolph C · The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2019

  11. 0.67

    Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil

    Samara M, Levine SZ, Yoshida K et al. · Journal of Alzheimer's disease : JAD · 2021

  12. 0.67

    Development of a straightforward and sensitive scale for MCI and early AD clinical trials

    Huang Y, Ito K, Billing CBJ et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  13. 0.66

    Development of a novel cognitive composite outcome to assess therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS-Cog-Exec

    Jacobs DM, Thomas RG, Salmon DP et al. · Alzheimer's & dementia (New York, N. Y.) · 2020

  14. 0.66

    Optimal Weighting of Preclinical Alzheimer's Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer's Disease Clinical Trials

    Wang X, Jacobs D, Salmon DP et al. · International journal of statistics in medical research · 2023

  15. 0.63

    The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials

    Raghavan N, Samtani MN, Farnum M et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2013

  16. 0.60

    Extension and external validation of mapping between the Mini-Mental State Examination and the Clinical Dementia Rating scale in patients with Alzheimer's disease

    Brogaard NJ, Hahn-Pedersen JH, Gundgaard J et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  17. 0.60

    Improved statistical power of Alzheimer clinical trials by item-response theory: proof of concept by application to the activities of daily living scale

    Ard MC, Galasko DR, Edland SD · Alzheimer disease and associated disorders · 2013

  18. 0.60

    Multi-site video-based assessment with the NACC UDS-Version 3 battery: Design and participant experience in the V-Cog study

    Sachs BC, Latham LA, Isom S et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  19. 0.60

    The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease

    Doraiswamy PM, Kaiser L, Bieber F et al. · Alzheimer disease and associated disorders · 2001

  20. 0.59

    Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling

    Ueckert S, Plan EL, Ito K et al. · Pharmaceutical research · 2014

  21. 0.58

    ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions

    Schneider LS, Clark CM, Doody R et al. · Alzheimer disease and associated disorders · 2006

  22. 0.58

    Development of an UPSA Short Form for Use in Longitudinal Studies in the Early Alzheimer's Disease Spectrum

    Goldberg TE, Harvey PD, Devanand DP et al. · The journal of prevention of Alzheimer's disease · 2020

  23. 0.58

    The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials

    Rentz DM, Dekhtyar M, Sherman J et al. · The journal of prevention of Alzheimer's disease · 2016

  24. 0.58

    Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials

    Goldberg TE, Lee S, Devanand DP et al. · Journal of neurology, neurosurgery, and psychiatry · 2023

  25. 0.58

    The MMSE can yield biased and imprecise estimates of change: A novel IRT analysis of latent change scores from the A4 clinical trial

    Thomas ML, Edland SD, Duehring J · Psychological assessment · 2026

  26. 0.58

    Developing dementia prevention trials: baseline report of the Home-Based Assessment study

    Sano M, Egelko S, Donohue M et al. · Alzheimer disease and associated disorders · 2013

  27. 0.57

    Diagnostic accuracy of a self-administered digital cognitive test battery for differentiating early Alzheimer's disease from controls

    Rutt S, Tegethoff P, Taute M et al. · European archives of psychiatry and clinical neuroscience · 2026

  28. 0.57

    Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer's Disease: Evidence from the VIVA-MIND trial

    Duehring JA, Jacobs DM, Salmon DP et al. · The journal of prevention of Alzheimer's disease · 2026

  29. 0.56

    Development and Validity of Norms for Cognitive Dispersion on the Uniform Data Set 3.0 Neuropsychological Battery

    Kiselica AM, Kaser AN, Weitzner DS et al. · Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2024

  30. 0.55

    The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

    Donohue MC, Sperling RA, Salmon DP et al. · JAMA neurology · 2014

  31. 0.55

    Psychometric properties of the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial

    Potashman M, Pang M, Tahir M et al. · BMC geriatrics · 2023

  32. 0.55

    How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L

    Martin A, Meads D, Griffiths AW et al. · Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2019

  33. 0.54

    The Alzheimer's Disease Assessment Scale

    Mohs RC · International psychogeriatrics · 1996

  34. 0.54

    Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer's disease: A factor analysis

    Hendrix SB, Sano M, Lyketsos C et al. · International psychogeriatrics · 2025

  35. 0.54

    Sparse item testing of clinical scales in neurology trials to alleviate burden to patients

    Chen C, Novakovic A, Jamsen K et al. · Journal of neurology · 2024

  36. 0.54

    Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease

    Gillen TE, Gregg KM, Yuan H et al. · Psychopharmacology bulletin · 2001

  37. 0.51

    Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer's disease

    Hegedus E, Pakaski M, Gosztolya G et al. · PloS one · 2024

  38. 0.50

    Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials

    Andrews JS, Desai U, Kirson NY et al. · Alzheimer's & dementia (New York, N. Y.) · 2019

  39. 0.50

    Design of pilot studies to inform the construction of composite outcome measures

    Edland SD, Ard MC, Li W et al. · Alzheimer's & dementia (New York, N. Y.) · 2017

  40. 0.50

    ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI)

    Walsh SP, Raman R, Jones KB et al. · Alzheimer disease and associated disorders · 2006

04cerebrospinal fluid · biomarkers19편

  1. 0.89

    The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation

    Wang G, Li Y, Xiong C et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  2. 0.85

    Symmetric Centipolar Normalized Score (SCeNS): A standardization framework for fluid marker cross-comparability in Alzheimer's disease

    Timsina J, Chen Y, Liu M et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2026

  3. 0.81

    Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium

    Verberk IMW, Gouda M, Antwi-Berko D et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  4. 0.80

    Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, alpha-synuclein, and total tau in combination with Abeta(1-42)/Abeta(1-40)

    Vanderstichele H, Demeyer L, Janelidze S et al. · Alzheimer's research & therapy · 2017

  5. 0.78

    Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting

    Zeng X, Chen Y, Sehrawat A et al. · Molecular neurodegeneration · 2024

  6. 0.77

    Harmonization and standardization of biofluid-based biomarker measurements for AT(N) classification in Alzheimer's disease

    Giangrande C, Delatour V, Andreasson U et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2023

  7. 0.68

    An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-beta concentrations collected by lumbar puncture and indwelling lumbar catheter

    Lucey BP, Gonzales C, Das U et al. · Alzheimer's research & therapy · 2015

  8. 0.67

    Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease

    Kang JH, Vanderstichele H, Trojanowski JQ et al. · Methods (San Diego, Calif.) · 2012

  9. 0.67

    Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42

    Mattsson N, Zegers I, Andreasson U et al. · Biomarkers in medicine · 2012

  10. 0.65

    Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials

    Weiner MW, Kanoria S, Miller MJ et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  11. 0.64

    2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

    Weiner MW, Veitch DP, Aisen PS et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  12. 0.64

    An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels

    Petzold A, Chapman MD, Schraen S et al. · Experimental neurology · 2010

  13. 0.62

    Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

    Arneric SP, Batrla-Utermann R, Beckett L et al. · Journal of Alzheimer's disease : JAD · 2017

  14. 0.61

    The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception

    Weiner MW, Veitch DP, Aisen PS et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2013

  15. 0.59

    Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease

    Abbas S, Ferreira PCL, Bellaver B et al. · The journal of prevention of Alzheimer's disease · 2025

  16. 0.59

    The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

    Albert MS, DeKosky ST, Dickson D et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2011

  17. 0.58

    The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception

    Weiner MW, Veitch DP, Aisen PS et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2012

  18. 0.56

    Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative

    Weiner MW, Veitch DP · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  19. 0.51

    Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer's Disease

    Garbarino VR, Palavicini JP, Melendez J et al. · Research square · 2024

05intervention · randomized5편

  1. 0.88

    Clinical Data Interchange Standards in Clinical Trials on Alzheimer's Disease 이 논문

    Na R, Bae JB, Jung SH et al. · Psychiatry investigation · 2022

  2. 0.60

    Impacts of informant replacement in two industry-sponsored Alzheimer's disease clinical trials

    Nishida MK, Nuno MM, Grill JD et al. · Alzheimer's & dementia (New York, N. Y.) · 2024

  3. 0.59

    ADCS Prevention Instrument Project: overview and initial results

    Ferris SH, Aisen PS, Cummings J et al. · Alzheimer disease and associated disorders · 2006

  4. 0.58

    Current Alzheimer's disease clinical trials: methods and placebo outcomes

    Schneider LS, Sano M · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2009

  5. 0.52

    Determining the minimum clinically important differences for outcomes in the DOMINO trial

    Howard R, Phillips P, Johnson T et al. · International journal of geriatric psychiatry · 2011

06imaging · brain5편

  1. 0.80

    The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months

    Simmons A, Westman E, Muehlboeck S et al. · International journal of geriatric psychiatry · 2011

  2. 0.68

    Japanese Alzheimer's Disease Neuroimaging Initiative: present status and future

    Iwatsubo T · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2010

  3. 0.68

    Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years

    Kapoor A, Bartha R, Black SE et al. · Journal of Alzheimer's disease : JAD · 2020

  4. 0.55

    Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease

    Teipel SJ, Grothe M, Lista S et al. · The Medical clinics of North America · 2013

  5. 0.51

    Characterizing amyloid and tau PET-based stages across the clinical continuum

    Cody KA, Sokolowski A, Johns E et al. · medRxiv : the preprint server for health sciences · 2025

07review · therapeutic5편

  1. 0.72

    The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders

    Schwarz AJ · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021

  2. 0.72

    European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)

    Duzel E, Acosta-Cabronero J, Berron D et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2019

  3. 0.59

    Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases

    Stephenson D, Aviles E, Bain LJ et al. · Therapeutic innovation & regulatory science · 2013

  4. 0.54

    Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup

    Sperling RA, Jack CRJ, Black SE et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2011

  5. 0.51

    Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Trial: Genetic Resource for Precision Nutrition

    Liu Y, Fowler H, Wang DD et al. · Nutrients · 2025

08review · meta-analysis2편

  1. 0.72

    Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review

    Christa Maree Stephan B, Minett T, Pagett E et al. · BMJ open · 2013

  2. 0.71

    Measurement tools of resource use and quality of life in clinical trials for dementia or cognitive impairment interventions: A systematically conducted narrative review

    Yang F, Dawes P, Leroi I et al. · International journal of geriatric psychiatry · 2018